ALEXANDER STOJADINOVIC ET AL: "Quantification and Phenotypic Characterization of Circulating Tumor Cells for Monitoring Response to a Preventive HER2/neu Vaccine-Based Immunotherapy for Breast Cancer: A Pilot Study", ANNALS OF SURGICAL ONCOLOGY, SPRINGER-VERLAG, NE, vol. 14, no. 12, 29 September 2007 (2007-09-29), pages 3359-3368, XP019547521, ISSN: 1534-4681, DOI: 10.1245/S10434-007-9538-X (B1)

BARRETT CIARA ET AL: "Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?", JOURNAL OF CLINICAL PATHOLOGY JUN 2007, vol. 60, no. 6, June 2007 (2007-06), pages 690-693, ISSN: 0021-9746 (B1)

DEHQANZADA ZIA A ET AL: "Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex (R) technology", ONCOLOGY REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 17, no. 3, 1 March 2007 (2007-03-01), pages 687-394, XP009112817, ISSN: 1021-335X (B1)

G. E. PEOPLES ET AL: "Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02", CLINICAL CANCER RESEARCH, vol. 14, no. 3, 1 February 2008 (2008-02-01), pages 797-803, XP55029043, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1448 (B1)

HUEMAN MATTHEW T ET AL: "Clinical trial results of a HER2/neu peptide (E75) vaccine in preventing recurrence in node positive breast cancer patients.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 45, March 2004 (2004-03), page 325, XP9160008, & 95TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ORLANDO, FL, USA; MARCH 27 -31, 2004 ISSN: 0197-016X (B1)

KHOO S ET AL: "HER2/neu vaccines in breast cancer", WOMEN'S HEALTH, FUTURE MEDICINE, UK, vol. 2, no. 2, 1 March 2006 (2006-03-01), pages 217-223, XP009160016, ISSN: 1745-5057, DOI: 10.2217/17455057.2.2.217 (B1)

US-A9- 2004 121 946 (B1)

MURRAY JAMES L ET AL: "Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NOV 2002 LNKD- PUBMED:12429628, vol. 8, no. 11, November 2002 (2002-11), pages 3407-3418, XP002677424, ISSN: 1078-0432 (B1)

PEOPLES G E ET AL: "Combined clinical trial results of a HER2/neu (E75) vaccine for prevention of recurrence in high-risk breast cancer patients", BREAST CANCER RESEARCH AND TREATMENT; 29TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM; SAN ANTONIO, TX, USA, SPRINGER, NEW YORK, NY, vol. 100, no. supplement 1, 1 January 2006 (2006-01-01), page S6, XP009160015, ISSN: 0167-6806 (B1)

PEOPLES GEORGE E ET AL: "Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 23, no. 30, 20 October 2005 (2005-10-20), pages 7536-7545, XP002546156, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.03.047 [retrieved on 2005-09-12] (B1)

TUBBS R R ET AL: "Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 19, no. 10, 15 May 2001 (2001-05-15), pages 2714-2721, XP002600920, ISSN: 0732-183X (B1)

US-A1- 2005 202 035 (B1)

MENENDEZ J A ET AL: "Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 24, no. 23, 10 August 2006 (2006-08-10), pages 3735-3746, XP002495702, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.04.3489 (B1)